Investment doubled the expansion of the plant, Baxter Deep in China's high-end infusion market

Li Yifi International Limited (NYSE:BA X) has passed a 146 million-dollar investment plan to expand its factories in Guangzhou, Suzhou, Tianjin and Shanghai.　　That figure is one-fold more than the pledge made by Baxter China 3 years ago to "invest 60 million dollars in capacity expansion". has become the largest growth market in the Asia-Pacific region "Our investment illustrates the importance of China's continued geographical expansion and business growth," Robert Parkinson, chief executive and CEO of Baxter, ERT L. Parkinson said, "More than 60% of the income from outside the United States." "Baxter China 2008 sales of about 200 million U.S. dollars."　　As a pharmaceutical company that produces specialist prescription drugs such as intravenous infusion and peritoneal dialysis, this figure has underpinned China's growth as the fastest growing market in the Asia-Pacific region. Continue to overweight high-end infusion market Varjak (Paul Vibert) said that Baxter in Guangzhou region's increase in capital is not included in August 2007 and Baiyun Mountain shares joint venture Guangzhou hundred Qiao Guang Medical Supplies Co., Ltd., but another joint venture with Canton Hundred Special Medical Supplies Co., Ltd. Guangzhou.　　In the continued loss of overseas Chinese, the fund was still adding 48 million dollars last year.　　With the enactment of the new medical reform policy, the Chinese government will give more financial support to the low-end drugs, especially the essential drugs, and how will the foreign drug companies respond? Expert analysis, foreign drug enterprises high-end products want to enter the list of basic drugs or health care directory has always been not dominant, but the performance of profits generally better than domestic drug companies. With the Japanese mass graves, Germany fee card, such as the continued increase in the Chinese market, high-end infusion market concentration increased, domestic pharmaceutical enterprises should be early thinking, can not be limited in the profit margin of the low-end product line spinning.